Come join others currently navigating treatment in our weekly Virtual Support Groups! See times and register here.
We've made it easier for you to connect! Fill out your NEW profile.

Clinical Trial for Metastatic TNBC Now Recruiting

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

Description

This phase I trial tests the safety, side effects, and best dose of CF33-hNIS-antiPDL1 in treating patients with triple negative breast cancer that has spread to other places in the body (metastatic). CF33-hNIS-antiPDL1 is an oncolytic virus. This is a virus that is designed to infect tumor cells and break them down.